The Experts below are selected from a list of 10857 Experts worldwide ranked by ideXlab platform
Tilman Todenhöfer - One of the best experts on this subject based on the ideXlab platform.
-
1320 altered expression of farnesyl pyrophosphate synthase in prostate cancer evidence for a role of the Mevalonate Pathway for disease progression
The Journal of Urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Ulrich Vogel, Stefan Aufderklamm, Arnulf Stenzl, Christian SchwentnerAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
-
1320 ALTERED EXPRESSION OF FARNESYL PYROPHOSPHATE SYNTHASE IN PROSTATE CANCER – EVIDENCE FOR A ROLE OF THE Mevalonate Pathway FOR DISEASE PROGRESSION
The Journal of Urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Ulrich Vogel, Stefan Aufderklamm, Arnulf Stenzl, Christian SchwentnerAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
-
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the Mevalonate Pathway in disease progression?
World journal of urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Georgios Gakis, Ulrich Vogel, Stefan Aufderklamm, Axel S. Merseburger, Judith Knapp, Arnulf StenzlAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
Arnulf Stenzl - One of the best experts on this subject based on the ideXlab platform.
-
1320 altered expression of farnesyl pyrophosphate synthase in prostate cancer evidence for a role of the Mevalonate Pathway for disease progression
The Journal of Urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Ulrich Vogel, Stefan Aufderklamm, Arnulf Stenzl, Christian SchwentnerAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
-
1320 ALTERED EXPRESSION OF FARNESYL PYROPHOSPHATE SYNTHASE IN PROSTATE CANCER – EVIDENCE FOR A ROLE OF THE Mevalonate Pathway FOR DISEASE PROGRESSION
The Journal of Urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Ulrich Vogel, Stefan Aufderklamm, Arnulf Stenzl, Christian SchwentnerAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
-
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the Mevalonate Pathway in disease progression?
World journal of urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Georgios Gakis, Ulrich Vogel, Stefan Aufderklamm, Axel S. Merseburger, Judith Knapp, Arnulf StenzlAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
Christian Schwentner - One of the best experts on this subject based on the ideXlab platform.
-
1320 ALTERED EXPRESSION OF FARNESYL PYROPHOSPHATE SYNTHASE IN PROSTATE CANCER – EVIDENCE FOR A ROLE OF THE Mevalonate Pathway FOR DISEASE PROGRESSION
The Journal of Urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Ulrich Vogel, Stefan Aufderklamm, Arnulf Stenzl, Christian SchwentnerAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
-
1320 altered expression of farnesyl pyrophosphate synthase in prostate cancer evidence for a role of the Mevalonate Pathway for disease progression
The Journal of Urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Ulrich Vogel, Stefan Aufderklamm, Arnulf Stenzl, Christian SchwentnerAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
Stefan Aufderklamm - One of the best experts on this subject based on the ideXlab platform.
-
1320 altered expression of farnesyl pyrophosphate synthase in prostate cancer evidence for a role of the Mevalonate Pathway for disease progression
The Journal of Urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Ulrich Vogel, Stefan Aufderklamm, Arnulf Stenzl, Christian SchwentnerAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
-
1320 ALTERED EXPRESSION OF FARNESYL PYROPHOSPHATE SYNTHASE IN PROSTATE CANCER – EVIDENCE FOR A ROLE OF THE Mevalonate Pathway FOR DISEASE PROGRESSION
The Journal of Urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Ulrich Vogel, Stefan Aufderklamm, Arnulf Stenzl, Christian SchwentnerAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
-
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the Mevalonate Pathway in disease progression?
World journal of urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Georgios Gakis, Ulrich Vogel, Stefan Aufderklamm, Axel S. Merseburger, Judith Knapp, Arnulf StenzlAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
Ulrich Vogel - One of the best experts on this subject based on the ideXlab platform.
-
1320 altered expression of farnesyl pyrophosphate synthase in prostate cancer evidence for a role of the Mevalonate Pathway for disease progression
The Journal of Urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Ulrich Vogel, Stefan Aufderklamm, Arnulf Stenzl, Christian SchwentnerAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
-
1320 ALTERED EXPRESSION OF FARNESYL PYROPHOSPHATE SYNTHASE IN PROSTATE CANCER – EVIDENCE FOR A ROLE OF THE Mevalonate Pathway FOR DISEASE PROGRESSION
The Journal of Urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Ulrich Vogel, Stefan Aufderklamm, Arnulf Stenzl, Christian SchwentnerAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.
-
Altered expression of farnesyl pyrophosphate synthase in prostate cancer: evidence for a role of the Mevalonate Pathway in disease progression?
World journal of urology, 2012Co-Authors: Tilman Todenhöfer, Jörg Hennenlotter, Ursula Kühs, Valentina Gerber, Georgios Gakis, Ulrich Vogel, Stefan Aufderklamm, Axel S. Merseburger, Judith Knapp, Arnulf StenzlAbstract:Background Preclinical studies demonstrated effects of drugs inhibiting the Mevalonate Pathway including nitrogen-containing bisphosphonates (N-BPs) and statins on tumor growth and progression. The exact role of this Pathway in prostate cancer (PC) has not been identified yet. Herein, we evaluate the expression of farnesyl pyrophosphate synthase (FPPS), the key enzyme of the Mevalonate Pathway, in PC.